<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="../../index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="../../index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="../titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="../parts/21CFR312.html">Part 312
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 312.140  Address for correspondence.
                            </h3>
                            <p class="depth1"><em>(a)</em> A sponsor must send an initial IND submission to the Center for  Drug Evaluation and Research (CDER) or to the Center for Biologics  Evaluation and Research (CBER), depending on the Center responsible for  regulating the product as follows:</p><p class="depth2"><em>(1)</em> For drug products regulated by CDER. Send the IND submission to  the Central Document Room, Center for Drug Evaluation and Research, Food  and Drug Administration, 5901-B Ammendale Rd., Beltsville, MD 20705- 1266; except send an IND submission for an in vivo bioavailability or  bioequivalence study in humans to support an abbreviated new drug  application to the Office of Generic Drugs (HFD-600), Center for Drug  Evaluation and Research, Food and Drug Administration, Metro Park North  VII, 7620 Standish Pl., Rockville, MD 20855.</p><p class="depth2"><em>(2)</em> For biological products regulated by CDER. Send the IND  submission to the CDER Therapeutic Biological Products Document Room,  Center for Drug Evaluation and Research, Food and Drug Administration,  12229 Wilkins Ave., Rockville, MD 20852.</p><p class="depth2"><em>(3)</em> For biological products regulated by CBER. Send the IND  submission to the Document Control Center (HFM-99), Center for Biologics  Evaluation and Research, Food and Drug Administration, 1401 Rockville  Pike, suite 200N, Rockville, MD 20852-1448.</p><p class="depth1"><em>(b)</em> On receiving the IND, the responsible Center will inform the  sponsor which one of the divisions in CDER or CBER is responsible for  the IND. Amendments, reports, and other correspondence relating to  matters covered by the IND should be sent to the appropriate center at  the address indicated in this section and marked to the attention of the  responsible division. The outside wrapper of each submission shall state  what is contained in the submission, for example, ``IND Application'',  ``Protocol Amendment'', etc.</p><p class="depth1"><em>(c)</em> All correspondence relating to export of an investigational drug  under Sec. 312.110(b)(2) shall be submitted to the International  Affairs Staff (HFY-50), Office of Health Affairs, Food and Drug  Administration, 5600 Fishers Lane, Rockville, MD 20857.  [70 FR 14981, Mar. 24, 2005, as amended at 74 FR 13113, Mar. 26, 2009;  74 FR 55771, Oct. 29, 2009; 75 FR 37295, June 29, 2010]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
